Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Newel Health is an AI-driven digital medical device company focused on chronic disease management, and is also a certified SaMD legal manufacturer. Its business is not a general-purpose AI health assistant; instead, it develops, certifies, and deploys digital medical devices for regulated healthcare settings, covering cardiometabolic diseases, Parkinson’s disease, and chronic pain. The company is headquartered in Salerno, Italy, and has a presence in multiple cities; its website lists Shenzhen.
Its core platform is H.Core, which brings together a quality management system, a library of pre-certified clinical modules, a behavioral science engine, and an AI/ML layer based on real-world clinical data. The website emphasizes the use of AI to make care more adaptive, timely, and personalized, while supporting continuous monitoring, patient engagement, and improvements to clinical models. Its current pipeline includes Amicomed for hypertension, Rohkea™ for chronic musculoskeletal pain using VR CBT, and Soturi for Parkinson’s disease dose management. Two products have received CE MDR Class IIa certification and are in the clinical deployment/commercialization stage.
The website does not publicly disclose pricing, plans, or free trials. Its model is clearly B2B-oriented: first, licensing certified products to pharmaceutical companies and healthcare systems; second, acting as a SaMD legal manufacturer to co-develop digital endpoints, companion therapies, and patient support programs with pharmaceutical or medtech companies, while taking regulatory responsibility from design controls through post-market surveillance. As a result, procurement is closer to enterprise-level customized collaboration.
Its strengths lie in a relatively strong compliance foundation, with frameworks such as ISO 13485, ISO 9001, ISO 27001, IEC 62304, EU MDR, GDPR, and HIPAA listed. It also already has certified products, rather than just proof-of-concept projects. The combination of behavioral science, AI, and real-world data is also well aligned with the needs of long-term chronic disease management. The limitations are that public materials do not disclose specific model architectures, algorithm performance, detailed clinical study results, data storage methods, or pricing. For ordinary patients or developers, there is also no self-service registration, API documentation, or trial entry point.
Newel Health is better suited to pharmaceutical companies, medical device companies, healthcare systems, and digital therapeutics teams looking to co-develop or adopt compliant digital medical products. It is less suitable as an AI health tool for individual direct use. The official website does not clarify access or payment information for China, so this is currently unknown. Although the website lists Shenzhen, it does not disclose a Chinese interface, local payment options, mainland China data compliance, or a China registration pathway. If deployed in China, key issues would still include network accessibility, medical device regulation, cross-border data transfer, and local alternatives.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on newel.health official site.
newel.health is an Italy AI Apps provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach newel.health directly.